Peptides in Parkinson’s Disease

  • André Barbeau
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 113)


Peptides have found a progressively more important role in the biochemistry and physiology of the brain in recent years. Many possess neurological and behavioral actions in addition to their function in endocrinology. This paper reviews the formation and distribution, as well as the neurological action, of peptides probably involved in Parkinson’s disease: β-LPH and its derivatives (MSH, ACTH4+10, β-endorphin). It also recounts the experience of many authors with prolyl-leucyl-glycine-amide (PLG) in that disease. Finally we propose a new theory of the etiology of Parkinson’s disease, based on a postulated deficiency in the important trophic function upon catecholaminergic neurons of A.P.U.D. cells.


Luteinizing Hormone Release Hormone Catecholaminergic Neuron Melanocyte Stimulate Hormone Motor Performance Test Striatal Dopamine Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barbeau, A. (1962). The pathogenesis of Parkinsons disease: a new hypothesis. Can. Med. Ass. J. 87, 802–807.PubMedGoogle Scholar
  2. Barbeau, A. (1973). Aging and the extrapyramidal system. J. Am. Geviat. Soc. 21, 145–149.Google Scholar
  3. Barbeau, A. (1975). Potentiation of L-DOPA effect by intravenous L-prolyl-L-leucyl-glycine amide in man. Lancet 2, 683.PubMedCrossRefGoogle Scholar
  4. Barbeau, A. (1976). Parkinson’s disease: Etiological considerations. In: The Basal Ganglia, pp. 281–292. Ed. M.D. Yahr. Raven Press, New York.Google Scholar
  5. Barbeau, A., Canpanella, G., Butterworth, R.F. and Yamada, K. (1975). Uptake and efflux of 14C- dopamine in platelets: Evidence for a generalized defect in Parkinson’s disease. Neurology 25, 1–9.PubMedCrossRefGoogle Scholar
  6. Barbeau, A., and Kastin, A.J. (1976). Polypeptide therapy in Parkinson’s disease — A new approach. In: Advances in Parkinsonism, pp. 483–487. Eds. W. Birkmayer and O. Horny-kiewicz. Editiones Roche, Basle.Google Scholar
  7. Barbeau, A., Rojo-Ortega, J.M. Brecht, H.M., Donaldson, J., Minnich, J.L. and Genest, J. (1972). Effect of a magnesium-deficient diet on the striatal content of amines in the dog. Experi-entia 28, 289–291. Google Scholar
  8. Barbeau, A., Roy, M. and Kastin, A.J. (1976). Double-blind evaluation of oral L-prolyl-L-leucyl-glycine amide in Parkinson’s disease. Can. Med. Ass. J. 114, 120–122.PubMedGoogle Scholar
  9. Butterworth, R.F. and Barbeau, A. (1975). Apomorphine: Stereotyped behaviour and regional distribution in rat brain. Can. J. Biochem. 53, 308–311.PubMedCrossRefGoogle Scholar
  10. Celis, M.E., Taleisnik, S. and Walter, R. (1971). Regulation of formation and proposed structure of the factor inhibiting the release of melanocyte-stimulating hormone. Proc. Natn. Acad. Sci. 68, 1428–1433.CrossRefGoogle Scholar
  11. Chase, T.N., Woods, A.C., Lipton, M.A. and Morris, C.E. (1974). Hypothalamic releasing factors and Parkinson’s disease. Arch. Neuro. 31, 55–56.CrossRefGoogle Scholar
  12. Chrétien, M. and Li, C.H. (1967). Isolation, purification and characterization of gammalipotropic hormone from sheep and pituitary glands. Can. J. Biochem. 45, 1163–1174.PubMedCrossRefGoogle Scholar
  13. Cotzias, G.C., Van Woert, M.H. and Schiffer, L.M. (1967). Aromatic amino acids and modifications of parkinsonism. New Engl. J. Med. 276, 374–379.PubMedCrossRefGoogle Scholar
  14. De Wied, D., Witter, A. and Lande, S. (1970). Anterior pituitary peptides and avoidance acquisition of hypophysectomized rats. In: Progress in Brain Research, Vol. 32, pp. 213–230. Eds. D. De Wied and J.A.W.M. Weinjneu. Elsevier Publishing Co., Amsterdam.Google Scholar
  15. Finch, C.E. (1973). Catecholamine metabolism in the brains of aging male mice. Brain Res. 52, 261–276.PubMedCrossRefGoogle Scholar
  16. Fischer, P.A., Schneider, E., Jacobi, P. and Maxion, H. (1974). Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson’s syndrome. Europ. Neurol. 12, 360–368.PubMedCrossRefGoogle Scholar
  17. Gamboa, E.T., Wolf, A., Yahr, M.D., Harter, D.H., Duffy, P.E., Barden, H. and Hsu, K.E. (1974). Influenza virus antigen in post-encephalitic parkinsonism brain. Arch. Neurol. 31, 228–232.PubMedCrossRefGoogle Scholar
  18. Gerstenbrand, F., Binder, H., Grünberger, J., Kozma, C., Push, S. and Reisner, T. (1976). Indusion therapy with MIF (melanocyte inhibiting factor) in Parkinson’s Disease. In: Advances in Parkinsonism, pp. 456–461. Eds. W. Birkmayer and O. Horny-kiewicz. Editiones Roche, Basle.Google Scholar
  19. Gonce, M. and Barbeau, A. (1977). Expériences thérapeutiques avec le Propyl-Leucyl-Glycine amide dans la maladie de Parkinson. Revue Neuro. (Paris), (in press).Google Scholar
  20. Hökfelt, T., Eide, R., Fuxe, Fl, Johansson, O., Ljungdahl, A., Golstein, M., Luft, R., Efendic, S., Nilsson, G., Terenuis, L., Ganten, D., Jeffcoate, S.L., Rehfeld, J., Said, S., Perez, de la Mora, M., Possani, L., Tapia, R., Teran, L. and Palacios, R. (1978). Aminergic and peptidergic pathways in the nervous system with special reference to the hypothalamus. In: The Hypothalamus, pp. 69–135. Eds. S. Reichlin, B.J. Baldessarini and J.B. Martin. Raven Press, New York. Google Scholar
  21. Hughes, J., Smith, T.W., Kosterlitz, H.W., Fothergill, L.A., Morgan, A.B. and Morris, H.R. (1975). Identification of two Related pentapeptides from the brain with potent opiate agonist activity. Nature 258, 577–579.PubMedCrossRefGoogle Scholar
  22. Izumi, K., Donaldson, J. and Barbeau, A. (1973). Yawning and stretching in rats induced by intraventricularly administered zinc. Life Sci. 12, 203–210.CrossRefGoogle Scholar
  23. Izumi, K., Motomatsu, T., Chrétien, M., Butterworth, R.F., Lis, M., Seidah, N. and Barbeau, A. (1977). ß-endorphin induced akinesia in rats: effect of apomorphine and a-methyl-p-tyrosine and related modifications of dopamine turnover in the basal ganglia. Life Sci. 20, 1149–1156.PubMedCrossRefGoogle Scholar
  24. Kastin, A.J. and Barbeau, A. (1972). Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson’s disease. Can. Med. Ass. J. 107, 1079–1081. PubMedGoogle Scholar
  25. Lycke, E. and Roos, B.E. (1969). Some virological and biochemical aspects of the pathogenesis of Parkinson’s disease. In: Third Symposium on Parkinson’s Disease, pp. 16–21. Eds. F.J. Gillingham and I.M.C. Donalson. E. and S. Livingstone Ltd., Edinburgh. Google Scholar
  26. Mobley, W.C., Server, A.C., Ishii, D.N., Riopelle, R.J. and Shooter, E.M. (1977). Nerve Growth Factor, Parts 1, 2 and 3. NewEngl. J. Med. 297, 1096–1104; 1149–1158; 1211–1218.CrossRefGoogle Scholar
  27. Moskowitz, M.A. and Wurtman, R.J. (1975). Catecholamines and neurologic diseases. Parts I and II. New Engl. J. Med. 293, 274–280; 332–338.PubMedCrossRefGoogle Scholar
  28. Nair, R.M.G., Kastin, A.J. and Schally, A.V. (1971). Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochem. Biophys. Res. Comm. 43, 1376–1381.PubMedCrossRefGoogle Scholar
  29. Pearse, A.G.E. (1969). The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologie, physiologic and pathologic implications of the concept. J. Histochem. Cytochem. 17, 303–313.PubMedCrossRefGoogle Scholar
  30. Plotnikoff, N.P. and Kastin, A.J. (1974). Pharmacological studies with a tripeptide, prolyl-leucyl-glycine amide. Arch. int.Pharmooodyn. Ther, 211, 211–224.Google Scholar
  31. Shuster, S., Thody, A.Y., Goolamali, S.K., Burton, J.L., Plummer, N. and Bates, D. (1973). Melanocyte-stimulating hormone and parkinsonism. Lancet i, 463–464.CrossRefGoogle Scholar
  32. Steiner, D.F. and Oyer, P.E. (1967). The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma. Proa. Natn. Acad. Sci. 57, 473–480.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • André Barbeau
    • 1
  1. 1.Department of NeurobiologyClinical Research Institute of MontrealMontrealCanada

Personalised recommendations